Related Experiment Videos
Post-transplant acute myeloid leukemia (PT-AML)
R Thalhammer-Scherrer1, G Wieselthaler, P Knoebl
1Department of Internal Medicine I, University of Vienna, Austria.
Leukemia
|March 23, 1999
Summary
Post-transplant acute myeloid leukemia (PT-AML) is rare but presents with diverse FAB classifications and molecular changes. Standard chemotherapy, with reduced immunosuppression, shows a 56% complete remission rate in these patients.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Acute myeloid leukemia (AML) is a rare complication post-organ transplantation (PT-AML).
- Few cases of PT-AML have been documented in medical literature.
- Understanding PT-AML is crucial due to increasing transplant numbers.
Observation:
- Three patients developed AML (FAB M1, M5, M4) after renal, lung, or liver transplantation.
- Molecular analysis revealed t(9;11) in one patient and confirmed recipient origin in another.
- Patients received chemotherapy, with adjusted immunosuppression regimens.
Findings:
- PT-AML occurs a median of 5 years post-transplant, with variable latency.
- The condition is heterogeneous, exhibiting chromosomal and molecular changes similar to therapy-related AML.
- Standard chemotherapy achieved a 56% complete remission rate, with a median remission duration of 4.6 months.
Implications:
- Standard chemotherapy is feasible and effective in managing PT-AML after reducing immunosuppression.
- Key complications include early mortality (25%), septicemia, and disease progression.
- This review offers diagnostic and therapeutic guidelines for managing PT-AML.